Concepts (303)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis B | 18 | 2021 | 172 | 2.900 |
Why?
|
| Hepatitis B virus | 12 | 2020 | 141 | 2.570 |
Why?
|
| Hepacivirus | 10 | 2023 | 272 | 1.320 |
Why?
|
| Hepatitis C | 9 | 2023 | 386 | 1.210 |
Why?
|
| DNA, Viral | 15 | 2020 | 487 | 1.110 |
Why?
|
| HIV-1 | 15 | 2002 | 477 | 1.050 |
Why?
|
| Liver Failure, Acute | 2 | 2016 | 94 | 0.870 |
Why?
|
| Blood Donors | 5 | 2011 | 60 | 0.860 |
Why?
|
| Hepatitis B Surface Antigens | 9 | 2017 | 55 | 0.840 |
Why?
|
| Insulin Resistance | 2 | 2023 | 697 | 0.840 |
Why?
|
| RNA, Viral | 11 | 2011 | 562 | 0.830 |
Why?
|
| Viral Load | 6 | 2017 | 404 | 0.690 |
Why?
|
| Transfusion Reaction | 4 | 2011 | 39 | 0.650 |
Why?
|
| Hepatitis B, Chronic | 4 | 2020 | 86 | 0.630 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2015 | 253 | 0.550 |
Why?
|
| Antiviral Agents | 5 | 2021 | 822 | 0.530 |
Why?
|
| Hepatitis B Vaccines | 5 | 2021 | 45 | 0.470 |
Why?
|
| Thymidine | 1 | 2015 | 53 | 0.460 |
Why?
|
| Blood Transfusion | 3 | 2009 | 291 | 0.450 |
Why?
|
| Jaundice | 1 | 2014 | 27 | 0.450 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2014 | 123 | 0.410 |
Why?
|
| Hepatitis A | 2 | 2007 | 31 | 0.390 |
Why?
|
| HIV Infections | 12 | 2002 | 2035 | 0.380 |
Why?
|
| Models, Statistical | 1 | 2014 | 492 | 0.370 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2015 | 496 | 0.370 |
Why?
|
| Polymerase Chain Reaction | 9 | 2011 | 1548 | 0.360 |
Why?
|
| Hepatitis A Vaccines | 3 | 2007 | 10 | 0.320 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 3 | 2001 | 70 | 0.310 |
Why?
|
| Infectious Disease Incubation Period | 1 | 2009 | 9 | 0.300 |
Why?
|
| Autophagy | 1 | 2012 | 426 | 0.300 |
Why?
|
| Algorithms | 2 | 2021 | 1728 | 0.300 |
Why?
|
| Homeostasis | 1 | 2012 | 721 | 0.280 |
Why?
|
| Glucose | 1 | 2012 | 878 | 0.280 |
Why?
|
| Insulin | 1 | 2012 | 1168 | 0.270 |
Why?
|
| Hepatitis B Antibodies | 4 | 2017 | 24 | 0.260 |
Why?
|
| Humans | 60 | 2023 | 132062 | 0.250 |
Why?
|
| Molecular Sequence Data | 10 | 2013 | 3770 | 0.240 |
Why?
|
| Herpesvirus 6, Human | 4 | 1995 | 55 | 0.230 |
Why?
|
| Public Health | 1 | 2007 | 281 | 0.230 |
Why?
|
| Genome, Viral | 2 | 1998 | 179 | 0.230 |
Why?
|
| Liver | 8 | 2021 | 1797 | 0.230 |
Why?
|
| Genes, Viral | 2 | 2017 | 181 | 0.230 |
Why?
|
| Herpesviridae Infections | 4 | 1995 | 146 | 0.220 |
Why?
|
| Beclin-1 | 1 | 2023 | 30 | 0.210 |
Why?
|
| Specimen Handling | 2 | 1997 | 149 | 0.210 |
Why?
|
| HIV | 6 | 2011 | 187 | 0.210 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2023 | 59 | 0.210 |
Why?
|
| Viral Hepatitis Vaccines | 4 | 1997 | 19 | 0.190 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2023 | 175 | 0.190 |
Why?
|
| Eye Infections, Viral | 2 | 1992 | 28 | 0.190 |
Why?
|
| Viral Regulatory and Accessory Proteins | 2 | 2020 | 37 | 0.180 |
Why?
|
| West Nile Fever | 1 | 2003 | 139 | 0.180 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2023 | 445 | 0.170 |
Why?
|
| Trans-Activators | 2 | 2020 | 712 | 0.170 |
Why?
|
| HIV Seropositivity | 4 | 1995 | 127 | 0.160 |
Why?
|
| Signal Transduction | 1 | 2012 | 4703 | 0.160 |
Why?
|
| Antigen-Antibody Complex | 2 | 1997 | 64 | 0.160 |
Why?
|
| Acquired Immunodeficiency Syndrome | 5 | 1994 | 232 | 0.150 |
Why?
|
| Viral Proteins | 1 | 2001 | 358 | 0.150 |
Why?
|
| Skin Diseases | 1 | 2021 | 138 | 0.150 |
Why?
|
| Hepatitis C, Chronic | 3 | 2009 | 370 | 0.150 |
Why?
|
| Amino Acid Sequence | 5 | 2013 | 2669 | 0.150 |
Why?
|
| Recombinant Proteins | 4 | 2017 | 1347 | 0.150 |
Why?
|
| China | 2 | 2017 | 290 | 0.150 |
Why?
|
| Multiprotein Complexes | 1 | 2020 | 201 | 0.150 |
Why?
|
| Organoids | 1 | 2021 | 300 | 0.140 |
Why?
|
| Hepatitis Viruses | 1 | 1998 | 3 | 0.140 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 261 | 0.140 |
Why?
|
| Hepatitis C Antibodies | 2 | 1997 | 24 | 0.140 |
Why?
|
| Genotype | 4 | 2017 | 2697 | 0.140 |
Why?
|
| Hepatitis, Viral, Human | 1 | 1998 | 45 | 0.140 |
Why?
|
| Pichia | 1 | 2017 | 56 | 0.130 |
Why?
|
| Carcinogenesis | 1 | 2020 | 358 | 0.130 |
Why?
|
| Intestines | 1 | 2021 | 603 | 0.130 |
Why?
|
| Genetic Variation | 2 | 2007 | 1580 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 672 | 0.130 |
Why?
|
| Leukocytes, Mononuclear | 3 | 1996 | 354 | 0.130 |
Why?
|
| Stem Cells | 1 | 2021 | 732 | 0.120 |
Why?
|
| Proviruses | 1 | 1996 | 19 | 0.120 |
Why?
|
| Hepatocytes | 2 | 2020 | 237 | 0.120 |
Why?
|
| Erythrocyte Membrane | 1 | 1995 | 22 | 0.120 |
Why?
|
| CD4 Antigens | 1 | 1995 | 51 | 0.120 |
Why?
|
| Hepatitis A Virus, Human | 1 | 1995 | 9 | 0.120 |
Why?
|
| Interferon-alpha | 2 | 2007 | 246 | 0.110 |
Why?
|
| Erythrocytes | 1 | 1995 | 201 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1960 | 0.100 |
Why?
|
| Cellular Senescence | 1 | 1995 | 199 | 0.100 |
Why?
|
| Conserved Sequence | 1 | 1993 | 296 | 0.100 |
Why?
|
| Meckel Diverticulum | 1 | 1992 | 11 | 0.100 |
Why?
|
| Glycogen Synthase | 1 | 2012 | 7 | 0.100 |
Why?
|
| Glycogen Synthase Kinases | 1 | 2012 | 6 | 0.100 |
Why?
|
| Viremia | 4 | 1998 | 133 | 0.100 |
Why?
|
| Ibuprofen | 1 | 1992 | 41 | 0.100 |
Why?
|
| Liver Cirrhosis | 1 | 1999 | 898 | 0.100 |
Why?
|
| Viral Envelope Proteins | 1 | 2013 | 155 | 0.100 |
Why?
|
| Models, Biological | 2 | 2020 | 1443 | 0.090 |
Why?
|
| Cell Line | 4 | 2012 | 2719 | 0.090 |
Why?
|
| Disease Transmission, Infectious | 2 | 2011 | 84 | 0.090 |
Why?
|
| Base Sequence | 5 | 1995 | 2899 | 0.090 |
Why?
|
| Mutant Proteins | 1 | 2012 | 116 | 0.090 |
Why?
|
| Epitopes | 1 | 1993 | 436 | 0.090 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 1977 | 0.090 |
Why?
|
| Adult | 12 | 2017 | 31568 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 985 | 0.090 |
Why?
|
| Xenotropic murine leukemia virus-related virus | 1 | 2011 | 2 | 0.090 |
Why?
|
| Amino Acid Substitution | 1 | 2012 | 409 | 0.090 |
Why?
|
| Corneal Diseases | 1 | 1992 | 97 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 1992 | 215 | 0.080 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1992 | 237 | 0.080 |
Why?
|
| Sensitivity and Specificity | 7 | 1998 | 2146 | 0.080 |
Why?
|
| Pregnancy | 7 | 2015 | 7566 | 0.080 |
Why?
|
| Female | 14 | 2017 | 70712 | 0.080 |
Why?
|
| Retinal Diseases | 1 | 1992 | 179 | 0.080 |
Why?
|
| AIDS-Related Complex | 1 | 1989 | 2 | 0.080 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 1381 | 0.080 |
Why?
|
| Hemophilia A | 2 | 2004 | 25 | 0.080 |
Why?
|
| Alanine Transaminase | 1 | 2009 | 162 | 0.080 |
Why?
|
| Transcription, Genetic | 2 | 1995 | 1422 | 0.070 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2009 | 68 | 0.070 |
Why?
|
| Donor Selection | 1 | 2009 | 58 | 0.070 |
Why?
|
| Immunity, Herd | 1 | 2007 | 13 | 0.070 |
Why?
|
| Male | 15 | 2015 | 64922 | 0.070 |
Why?
|
| Carrier State | 1 | 2008 | 77 | 0.070 |
Why?
|
| Lymphocytes | 1 | 1989 | 362 | 0.070 |
Why?
|
| Mutation | 2 | 2017 | 6229 | 0.070 |
Why?
|
| Ribavirin | 1 | 2007 | 89 | 0.070 |
Why?
|
| Evaluation Studies as Topic | 2 | 1998 | 258 | 0.060 |
Why?
|
| Reproducibility of Results | 4 | 1998 | 3014 | 0.060 |
Why?
|
| Interferons | 1 | 2007 | 142 | 0.060 |
Why?
|
| Lamivudine | 1 | 2006 | 27 | 0.060 |
Why?
|
| Organophosphonates | 1 | 2006 | 21 | 0.060 |
Why?
|
| Drug Resistance, Viral | 1 | 2006 | 50 | 0.060 |
Why?
|
| Guanine | 1 | 2006 | 61 | 0.060 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2006 | 37 | 0.060 |
Why?
|
| Reference Standards | 2 | 1998 | 242 | 0.060 |
Why?
|
| Time Factors | 4 | 2007 | 6448 | 0.060 |
Why?
|
| Immunization, Secondary | 2 | 2021 | 113 | 0.060 |
Why?
|
| Adenine | 1 | 2006 | 120 | 0.060 |
Why?
|
| Liver Diseases | 2 | 2003 | 384 | 0.060 |
Why?
|
| HIV Antibodies | 4 | 1994 | 70 | 0.060 |
Why?
|
| Parvovirus B19, Human | 1 | 2004 | 31 | 0.060 |
Why?
|
| Drug Contamination | 1 | 2004 | 38 | 0.050 |
Why?
|
| Parvoviridae Infections | 1 | 2004 | 37 | 0.050 |
Why?
|
| Factor VIII | 1 | 2004 | 48 | 0.050 |
Why?
|
| Range of Motion, Articular | 1 | 2004 | 82 | 0.050 |
Why?
|
| Middle Aged | 5 | 2017 | 28964 | 0.050 |
Why?
|
| Preventive Medicine | 1 | 2003 | 21 | 0.050 |
Why?
|
| Virus Replication | 3 | 2020 | 630 | 0.050 |
Why?
|
| Antigens, Viral | 3 | 1995 | 437 | 0.050 |
Why?
|
| Hepatitis B Antigens | 2 | 1993 | 10 | 0.050 |
Why?
|
| Virus Cultivation | 2 | 2001 | 76 | 0.050 |
Why?
|
| Kidney Transplantation | 1 | 1988 | 570 | 0.050 |
Why?
|
| Cytomegalovirus | 2 | 1995 | 259 | 0.050 |
Why?
|
| Water Supply | 1 | 2002 | 26 | 0.050 |
Why?
|
| False Positive Reactions | 3 | 1998 | 142 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2021 | 3036 | 0.050 |
Why?
|
| Hygiene | 1 | 2002 | 24 | 0.050 |
Why?
|
| Infant, Newborn | 7 | 2002 | 8549 | 0.050 |
Why?
|
| History, 21st Century | 1 | 2003 | 272 | 0.050 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 1992 | 130 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2003 | 386 | 0.050 |
Why?
|
| Enterohepatic Circulation | 1 | 2021 | 11 | 0.040 |
Why?
|
| Serial Passage | 1 | 2001 | 19 | 0.040 |
Why?
|
| Dermatologists | 1 | 2021 | 5 | 0.040 |
Why?
|
| Glycosylation | 1 | 2001 | 126 | 0.040 |
Why?
|
| HIV Core Protein p24 | 3 | 1995 | 11 | 0.040 |
Why?
|
| Hepatitis Antibodies | 2 | 1997 | 5 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2020 | 94 | 0.040 |
Why?
|
| Infant | 7 | 2007 | 13064 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2001 | 749 | 0.040 |
Why?
|
| Morbidity | 1 | 2020 | 256 | 0.040 |
Why?
|
| Stomach | 1 | 2021 | 273 | 0.040 |
Why?
|
| Zidovudine | 2 | 2002 | 23 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2001 | 824 | 0.040 |
Why?
|
| Genes, gag | 2 | 1995 | 8 | 0.040 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1998 | 54 | 0.030 |
Why?
|
| Hepatovirus | 1 | 1997 | 17 | 0.030 |
Why?
|
| Serotyping | 1 | 1998 | 178 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2020 | 799 | 0.030 |
Why?
|
| Polysaccharide-Lyases | 1 | 1997 | 2 | 0.030 |
Why?
|
| Heparin Lyase | 1 | 1997 | 2 | 0.030 |
Why?
|
| Alcoholism | 1 | 1999 | 249 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 662 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 1997 | 60 | 0.030 |
Why?
|
| RNA Probes | 2 | 1995 | 30 | 0.030 |
Why?
|
| Autoradiography | 2 | 1995 | 67 | 0.030 |
Why?
|
| Alaska | 1 | 1996 | 5 | 0.030 |
Why?
|
| Animals | 3 | 2007 | 34882 | 0.030 |
Why?
|
| Protein Binding | 1 | 2020 | 1729 | 0.030 |
Why?
|
| HIV Antigens | 1 | 1995 | 12 | 0.030 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 1995 | 14 | 0.030 |
Why?
|
| Chronic Disease | 2 | 1998 | 1234 | 0.030 |
Why?
|
| Genes, env | 1 | 1995 | 9 | 0.030 |
Why?
|
| Heparin | 1 | 1997 | 212 | 0.030 |
Why?
|
| Blood Transfusion, Autologous | 1 | 1995 | 36 | 0.030 |
Why?
|
| Laboratories | 2 | 1994 | 89 | 0.030 |
Why?
|
| Kazakhstan | 2 | 2007 | 8 | 0.030 |
Why?
|
| Half-Life | 1 | 1995 | 161 | 0.030 |
Why?
|
| Global Health | 1 | 2020 | 643 | 0.030 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1995 | 136 | 0.030 |
Why?
|
| HIV Seronegativity | 1 | 1994 | 30 | 0.030 |
Why?
|
| Acute Disease | 1 | 1998 | 1160 | 0.030 |
Why?
|
| United States | 4 | 2007 | 11658 | 0.030 |
Why?
|
| Immunization Programs | 1 | 1995 | 65 | 0.030 |
Why?
|
| Antibodies, Viral | 3 | 2004 | 1203 | 0.030 |
Why?
|
| DNA Primers | 1 | 1995 | 636 | 0.030 |
Why?
|
| Hepatitis B e Antigens | 1 | 2013 | 13 | 0.030 |
Why?
|
| Dideoxyadenosine | 1 | 1993 | 3 | 0.030 |
Why?
|
| Hepatitis D | 1 | 1993 | 3 | 0.030 |
Why?
|
| Hemophilia B | 1 | 1993 | 8 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 1994 | 219 | 0.020 |
Why?
|
| Risk Factors | 4 | 2009 | 10941 | 0.020 |
Why?
|
| Helicobacter Infections | 1 | 2002 | 1278 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1993 | 651 | 0.020 |
Why?
|
| Patient Compliance | 1 | 1996 | 472 | 0.020 |
Why?
|
| DNA, Single-Stranded | 1 | 1992 | 69 | 0.020 |
Why?
|
| Serologic Tests | 1 | 1993 | 130 | 0.020 |
Why?
|
| Cryopreservation | 1 | 1992 | 71 | 0.020 |
Why?
|
| Virology | 1 | 1992 | 36 | 0.020 |
Why?
|
| DNA Probes | 1 | 1992 | 124 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 1995 | 828 | 0.020 |
Why?
|
| Point Mutation | 1 | 2013 | 348 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 1993 | 1694 | 0.020 |
Why?
|
| Anticoagulants | 1 | 1997 | 609 | 0.020 |
Why?
|
| Culture Media | 1 | 1992 | 183 | 0.020 |
Why?
|
| Retina | 1 | 1995 | 491 | 0.020 |
Why?
|
| Professional Competence | 1 | 1992 | 95 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2013 | 3418 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 1992 | 309 | 0.020 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2011 | 14 | 0.020 |
Why?
|
| DNA | 1 | 1997 | 1473 | 0.020 |
Why?
|
| Blood Banks | 1 | 2011 | 12 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 1994 | 488 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 1999 | 1103 | 0.020 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2011 | 71 | 0.020 |
Why?
|
| Hepatitis A Antibodies | 2 | 2002 | 9 | 0.020 |
Why?
|
| Sexual Partners | 1 | 2011 | 80 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 1993 | 540 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 1992 | 223 | 0.020 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1993 | 242 | 0.020 |
Why?
|
| Vaccination | 1 | 1996 | 1018 | 0.020 |
Why?
|
| Homosexuality | 1 | 1989 | 12 | 0.020 |
Why?
|
| Child | 5 | 2004 | 25789 | 0.020 |
Why?
|
| Inclusion Bodies | 1 | 1989 | 42 | 0.020 |
Why?
|
| North America | 1 | 1990 | 264 | 0.020 |
Why?
|
| Gastric Mucosa | 1 | 1992 | 491 | 0.020 |
Why?
|
| Safety | 1 | 2009 | 216 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 1989 | 220 | 0.020 |
Why?
|
| Phylogeny | 1 | 2011 | 764 | 0.020 |
Why?
|
| Prognosis | 1 | 1998 | 5009 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2002 | 3990 | 0.020 |
Why?
|
| Prevalence | 2 | 2007 | 2658 | 0.020 |
Why?
|
| Adolescent | 3 | 2002 | 20562 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 1992 | 794 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 1799 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2007 | 367 | 0.020 |
Why?
|
| Graft Survival | 1 | 1988 | 474 | 0.020 |
Why?
|
| Cornea | 1 | 1991 | 598 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2007 | 251 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2007 | 3761 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 3091 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1993 | 1738 | 0.010 |
Why?
|
| False Negative Reactions | 2 | 1995 | 89 | 0.010 |
Why?
|
| Predictive Value of Tests | 3 | 1995 | 2320 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 1180 | 0.010 |
Why?
|
| In Situ Hybridization | 2 | 1995 | 468 | 0.010 |
Why?
|
| Sex Factors | 1 | 2007 | 1353 | 0.010 |
Why?
|
| Patient Selection | 1 | 2007 | 737 | 0.010 |
Why?
|
| Giant Cells | 1 | 2002 | 34 | 0.010 |
Why?
|
| Seroepidemiologic Studies | 1 | 2002 | 144 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 5409 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2002 | 792 | 0.010 |
Why?
|
| Antibodies, Bacterial | 1 | 2002 | 406 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 2445 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2002 | 898 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 2002 | 348 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2002 | 1436 | 0.010 |
Why?
|
| Age Factors | 1 | 2004 | 2912 | 0.010 |
Why?
|
| Prospective Studies | 1 | 1988 | 6567 | 0.010 |
Why?
|
| Vaccines, Inactivated | 1 | 1997 | 148 | 0.010 |
Why?
|
| Immunization | 1 | 1997 | 312 | 0.010 |
Why?
|
| Retinitis | 1 | 1995 | 16 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1995 | 249 | 0.010 |
Why?
|
| Blood Specimen Collection | 1 | 1994 | 47 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1994 | 251 | 0.010 |
Why?
|
| Fetal Blood | 1 | 1995 | 175 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2004 | 14751 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1993 | 213 | 0.010 |
Why?
|
| Hepatitis Delta Virus | 1 | 1993 | 6 | 0.010 |
Why?
|
| Helicobacter pylori | 1 | 2002 | 1336 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1995 | 822 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1993 | 196 | 0.010 |
Why?
|
| Digoxigenin | 1 | 1992 | 2 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 1993 | 169 | 0.010 |
Why?
|
| Phenotype | 1 | 2002 | 4529 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1993 | 216 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 1992 | 41 | 0.010 |
Why?
|
| Physical Examination | 1 | 1993 | 166 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1991 | 311 | 0.010 |
Why?
|
| Mice | 1 | 2006 | 18507 | 0.000 |
Why?
|
| Blotting, Western | 1 | 1991 | 1077 | 0.000 |
Why?
|
| Aged | 1 | 2002 | 21406 | 0.000 |
Why?
|
| Incidence | 1 | 1991 | 3380 | 0.000 |
Why?
|